SecurityEBRYY / Centrais Electricas Brazil (15234Q207)
Institutional Owners45
Institutional Shares8,293,352
Institutional Value$ 49,670,000 USD

Institutional Stock Ownership and Shareholders

Centrais Electricas Brazil (OTC:EBRYY) has 45 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 8,293,352 shares. Largest shareholders include Goldman Sachs Group Inc, Vanguard Group Inc, Citigroup Inc, Bienville Capital Management, LLC, Morgan Stanley, Aperio Group, LLC, UBS Group AG, Russell Investments Group, Ltd., State Street Corp, and Parametric Portfolio Associates Llc.

Centrais Electricas Brazil (OTC:EBRYY) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.


File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-01-16 13F-HR BANK OF MONTREAL /CAN/ 55 0 -100.00 0 0
2018-02-08 13F-HR PineBridge Investments, L.P. 61,061 348
2017-11-13 13F-HR EDMOND DE ROTHSCHILD HOLDING S.A. 26,000 0 -100.00 98 0 -100.00
2018-02-09 13F-HR Banco BTG Pactual S.A. 1,003,366 0 -100.00 6,221 0 -100.00
2018-02-20 13F-HR ENVESTNET ASSET MANAGEMENT INC 90 0 -100.00 1 0 -100.00
2018-02-09 13F-HR Connor, Clark & Lunn Investment Management Ltd. 122,603 55,093 -55.06 760 314 -58.68
2018-02-06 13F-HR Russell Investments Group, Ltd. 181,439 181,439 0.00 1,125 1,047 -6.93
2017-11-13 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 88 0 -100.00 0 0
2018-02-08 13F-HR WELLS FARGO & COMPANY/MN 16 3,016 18,750.00 0 17
2018-02-14 13F-HR GOLDMAN SACHS GROUP INC 4,517,686 3,638,205 -19.47 28,010 20,738 -25.96
2018-02-12 13F-HR Quantbot Technologies LP 1,700 9
2018-02-13 13F-HR MACKENZIE FINANCIAL CORP 10,800 62
2018-03-05 13F-HR/A-1 BNP PARIBAS ARBITRAGE, SA 412 412 0.00 2,554 2,348 -8.07
2018-02-09 13F-HR Virtu Financial LLC 54,997 25,600 -53.45 341 146 -57.18
2017-11-15 13F-HR/A-1 Parallel Advisors, LLC 47 0
2017-11-13 13F-HR CIBC World Markets Inc. 24,522 0 -100.00 92 0 -100.00
2018-02-14 13F-HR PARAMETRIC PORTFOLIO ASSOCIATES LLC 96,362 124,378 29.07 597 709 18.76
2018-02-14 13F-HR BARCLAYS PLC 30,900 21,500 -30.42 192 123 -35.94
2018-02-13 13F-HR Renaissance Technologies LLC 16,900 46,900 177.51 92 267 190.22
2018-02-14 13F-HR ROYAL BANK OF CANADA 3,503 2,000 -42.91 22 11 -50.00
2018-02-09 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 1,231 1,765 43.38 7 10 42.86
2018-02-12 13F-HR CITIGROUP INC 807,093 1,024,732 26.97 5,004 5,841 16.73
2018-02-14 13F-HR MORGAN STANLEY 362,847 229,908 -36.64 2,249 1,311 -41.71
2018-01-24 13F-HR IFP Advisors, Inc 156 156 0.00 1 1 0.00
2018-02-12 13F-HR DIMENSIONAL FUND ADVISORS LP 39,792 40,692 2.26 244 235 -3.69
2018-02-14 13F-HR NORTHERN TRUST CORP 44,703 42,569 -4.77 277 242 -12.64
2018-02-14 13F-HR Advisor Group, Inc. 2,549 1,200 -52.92 16 7 -56.25
2018-02-15 13F-HR JANE STREET GROUP, LLC 0 24,089 0 141
2018-02-09 13F-HR ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 509,059 34,022 -93.32 3,156 194 -93.85
2018-02-14 13F-HR Cubist Systematic Strategies, LLC 0 20,654 0 118
2018-02-02 13F-HR COMERICA BANK 58,455 58,356 -0.17 397 364 -8.31
2018-02-02 13F-HR US BANCORP \DE\ 2,561 2,561 0.00 16 15 -6.25
2017-11-09 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 35,402 0 -100.00 134 0 -100.00
2018-02-14 13F-HR VANGUARD GROUP INC 1,297,767 1,352,667 4.23 8,046 7,710 -4.18
2018-02-14 13F-HR MILLENNIUM MANAGEMENT LLC 86,237 0 -100.00 535 0 -100.00
2018-02-14 13F-HR Bienville Capital Management, LLC 89,106 344,106 286.18 552 1,961 255.25
2018-02-07 13F-HR LS Investment Advisors, LLC 130 130 0.00 1 1 0.00
2018-01-24 13F-HR BOSTON ADVISORS LLC 53,500 54,970 2.75 332 313 -5.72
2018-02-09 13F-HR Tower Research Capital LLC (TRC) 14 0 -100.00 0 0
2018-02-14 13F-HR HSBC HOLDINGS PLC 39,493 29,389 -25.58 245 168 -31.43
2018-02-14 13F-HR STATE STREET CORP 87,581 140,892 60.87 543 803 47.88
2018-02-26 13F-HR/A-1 Newfoundland Capital Management 35,302 0 -100.00 219 0 -100.00
2018-02-09 13F-HR Mitsubishi UFJ Trust & Banking Corp 0 45,684 0 260
2018-02-14 13F-HR GUGGENHEIM CAPITAL LLC 51,265 49,995 -2.48 318 285 -10.38
2018-04-04 13F-HR CENTRAL TRUST Co 500 500 0.00 3 3 0.00
2018-02-14 13F-HR MACQUARIE GROUP LTD 97,500 97,500 0.00 605 556 -8.10
2018-02-02 13F-HR Aperio Group, LLC 215,600 220,834 2.43 1,337 1,259 -5.83
2018-02-14 13F-HR BANK OF AMERICA CORP /DE/ 5,562 6,934 24.67 34 40 17.65
2017-11-09 13F-HR FTB Advisors, Inc. 68 0 -100.00 0 0
2018-02-14 13F-HR STIFEL FINANCIAL CORP 32,783 32,783 0.00 202 188 -6.93
2018-02-14 13F-HR UBS Group AG 189,599 186,839 -1.46 1,175 1,065 -9.36
2018-02-14 13F-HR FIFTH THIRD BANCORP 80 80 0.00 0 0
2018-04-18 13F-HR/A-1 FNY Partners Fund LP 10,000 0 -100.00 57 0 -100.00
2018-02-01 13F-HR Harel Insurance Investments & Financial Services Ltd. 22,876 3,276 -85.68 142 19 -86.62
2017-11-14 13F-HR BlackRock Inc. 32,975 0 -100.00 124 0 -100.00
2018-04-18 13F-HR Cornerstone Advisors, Inc. 0 371 0 2
2018-01-19 13F-HR Steward Partners Investment Advisory, Llc 100 100 0.00 0 0
2018-02-13 13F-HR JP Morgan Chase & Co 10,500 73,447 599.50 65 419 544.62

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 15234Q207